Ozmosi | Somatostatin Drug Profile
Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Somatostatin

Alternative Names: somatostatin
Clinical Status: Inactive
Latest Update: 2025-12-04
Latest Update Note: News Article

Product Description

Mechanisms of Action: SSTR Agonist

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: Austria | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Czech | Ecuador | Egypt | France | Germany | Greece | Hong Kong | India | Indonesia | Italy | Jordan | Korea | Luxembourg | Malta | Morocco | Pakistan | Peru | Philippines | Poland | Portugal | Saudi Arabia | Serbia | Singapore | Slovenia | South Africa | Spain | Switzerland | Taiwan | Turkey | United Arab Emirates | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

Recent News Events

Date

Type

Title

12/04/2025

News Article

 Perspective Therapeutics Announces Acceptance of VMT-Ī±-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium

12/03/2025

News Article

 Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors

11/20/2025

News Article

 Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome

11/12/2025

News Article

 AtomVie Global Radiopharma Supplies the First Patient Dose of 225Ac-SSO110 for Ariceum Therapeutics' Phase 1/2 SANTANA-225 Clinical Trial in Extensive-Stage Small Cell Lung Cancer and Merkel Cell Carcinoma

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions